Sales of eye care pharmaceuticals rose to $379.2 million at...

Sales of eye care pharmaceuticals rose to $379.2 million at Allergan for the second quarter ended June 30, or $54.2 million more than in the same period a year ago. Total revenues were up to $801.7 million from $594.6 million, with product revenues up by 33.2 percent, thanks in part ...

To continue reading this article subscribe now

Already an Eyewear Intelligence subscriber? Sign in here.


Become a member today for full access from just €6,70 a week!

Buying a membership today will give you:

  • Unlimited access to - all insight and analysis available online
  • Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
  • Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
  • Case studies and best practices on business challenges
  • Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
  • Access to over 11,500 articles and analyses in the archive
  • Personal library to save articles and track your key content
  • Powerful search and intuitive navigation

Or sign-up for a trial month for just 9,90€. To continue reading this article register now.